圣诺医药-B(02257.HK)完成试验药物STP707的I期试验并已向FDA正式提交临床研究报告

Group 1 - The core point of the article is that Sanofi Pharmaceutical-B (02257.HK) announced that its wholly-owned subsidiary, Sirnaomics, Inc., has completed the Phase I trial of the experimental drug STP707 and has formally submitted the clinical research report to the U.S. Food and Drug Administration (FDA) [1]